NCT06573645View on ClinicalTrials.gov

A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

428

Participants

Timeline

Start Date

August 23, 2024

Primary Completion Date

January 12, 2027

Study Completion Date

July 12, 2027

Conditions
Lymphoma, Large B-Cell, Diffuse
Interventions
DRUG

Rituximab

Patients will be randomized to receive either rituximab 500 mg/m2 or rituximab 375 mg/m2 for six cycles of R-CHOP (21 days per cycle), followed by two maintenance cycles of rituximab (21 days per cycle).

All Listed Sponsors
lead

Xia Yi

OTHER

NCT06573645 - A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL | Biotech Hunter | Biotech Hunter